268 related articles for article (PubMed ID: 18252711)
1. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
2. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.
Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME
J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.
Foley JH; Cook PF; Nesheim ME
J Biol Chem; 2011 Jun; 286(22):19280-6. PubMed ID: 21467042
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
5. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
6. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN
J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524
[TBL] [Abstract][Full Text] [Related]
8. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
9. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB
BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823
[TBL] [Abstract][Full Text] [Related]
10. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.
Valnickova Z; Thøgersen IB; Potempa J; Enghild JJ
J Biol Chem; 2007 Feb; 282(5):3066-76. PubMed ID: 17138567
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
13. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator.
Stewart RJ; Fredenburgh JC; Rischke JA; Bajzar L; Weitz JI
J Biol Chem; 2000 Nov; 275(47):36612-20. PubMed ID: 10970891
[TBL] [Abstract][Full Text] [Related]
14. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Meijers JC
J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
[TBL] [Abstract][Full Text] [Related]
16. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
Walker JB; Hughes B; James I; Haddock P; Kluft C; Bajzar L
J Biol Chem; 2003 Mar; 278(11):8913-21. PubMed ID: 12643276
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.
Zhao L; Buckman B; Seto M; Morser J; Nagashima M
J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]